An experimental cancer vaccine has shown a survival benefit in a late-stage trial involving people with acute myeloid leukemia, according to initial results announced on 17 November by its developer, SELLAS Life Sciences.
The finding is drawing attention because patients whose leukemia returns can face limited treatment options. But who took part in the study, and how far is the treatment from becoming available?
What did the REGAL trial find?
SELLAS reported that patients receiving galinpepimut-S, also called GPS, had a median overall survival of 24 months, compared with 14.7 months for patients receiving the investigator’s choice of best available treatment.
The company reported a hazard ratio of 0.59—a 41% relative reduction in the risk of death over the study period. That is a comparison between groups over time; it does not mean that 41% of all patients were cured.
The randomised, open-label phase 3 study included 126 participants. The comparison group could receive observation or other treatments selected by investigators.
Who was studied?
The trial focused on a specific group: people with acute myeloid leukemia (AML) who had reached a second or later remission after their disease returned and who were ineligible for, or unable to undergo, an allogeneic stem cell transplant.
The reported result should therefore be understood in that setting. It does not establish that the vaccine benefits every person with AML or people with other cancers.
How does the vaccine work?
GPS is an investigational therapeutic vaccine designed to stimulate an immune response against WT1, a protein found in many leukemia cells. It uses synthetic peptides and was discovered by researchers at Memorial Sloan Kettering Cancer Center, which licensed it to SELLAS.
A therapeutic cancer vaccine is intended to help treat an existing disease. Its purpose differs from a vaccine given to prevent an infection.
Is the leukemia vaccine approved?
The treatment remains experimental. SELLAS says it plans discussions with the US Food and Drug Administration and is preparing an application; approval and its timing are not guaranteed.
The announcement presents topline results. Detailed analyses and full safety data will help clinicians assess the findings. SELLAS reported that treatment-related side effects were mainly mild to moderate, commonly including reactions at the injection site, and that it identified no new safety signals.
The early survival result is encouraging for the particular population studied. Full reporting and regulatory review are the next steps before the treatment’s role in care can be established.